List view / Grid view
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
A report indicates ongoing demand for COVID-19 vaccines and other biologics, as well as increasing investment will drive a 16.6 percent CAGR in the bioreactors market.
The approval of at least one new manufacturing site based in Europe for each of the approved COVID-19 vaccines should increase supply for the EU.
The emergence of CAR T-cell therapies has ignited a revolution in the field of cancer treatments. While existing products show outstanding curative capability, they are hampered by significant clinical and commercial challenges, many of which stem from their manufacturing process. Maciej Nakoniecznik discusses how a combination of biological and technological advances…
In this in-depth focus, discover how biological and technological advances could enhance the clinical capabilities of CAR T-cell therapies and explore why clinicians need to be better educated about the development and licencing of biosimilars.
In this issue we discuss whether clinicians know enough about the development of biosimilars to buy in, explore the biggest M&A trends in pharma and what to expect this year and consider the importance of disaccharides in the stabilisation of biologics. The journal also features articles on the fundamentals of…
The UK Government has ordered a further 40 million doses of Valneva’s COVID-19 vaccine candidate, to be manufactured in Scotland.
Researchers have developed a novel high-throughput method for the detection of glycans in purified biopharmaceutical samples. In this article, Victoria Smith, Lewis Wharram and Stuart Jamieson discuss their innovative approach and the implications for safety and potency assurance in biopharmaceuticals.
In this in-depth focus learn about the development and implications of a novel high-throughput method for glycoanalytics and how taking a full-ecosystem approach to microbiome restoration could improve patient survival.
European Pharmaceutical Review spoke with Dean Petkanas from Neuropathix, formerly known as Kannalife, to find out why a CBD-inspired molecule can offer an improved therapeutic value.
A new analysis suggests that Europe and North America will capture more than 80 percent of the $9.3 billion market by 2030.
Adoptive T-cell transfer therapy has had limited use due to the time involved in CD8+ T cell expansion, using a different type of T cell researchers were able to shorten this timeline, making the therapy more accessible.
A new report has found that if COVID-19 biologics are approved, it could apply pressure to the global biomanufacturing capacity.
Researchers who developed the dissolvable microcarrier for large-scale cell production and expansion say it offers higher yield and cost-effectiveness compared to traditional methods.
Articles in this in-depth focus discuss the challenges facing advanced therapy medicinal product developers and which leadership qualities could be implemented to drive innovation in biologics.
